Morphological effects in the mouse myocardium after methylenedioxymethamphetamine administration combined with loud noise exposure.
Early toxicity occurring during or immediately after 3,4-methylenedioxymethamphetamine (MDMA, or "ecstasy") administration has not been investigated in detail, although in humans it is responsible for marked side effects, and even death. Acute toxicity induced by MDMA produces rhabdomyolysis involving the myocardium (myocytolysis). Cardiac symptoms, such as tachycardia, hypertension, and arrhythmia, are present to a variable extent in humans abusing ecstasy. In most cases, this substance is abused in the presence of loud noise, which may affect the myocardium. Despite the frequency of the concomitant exposure to ecstasy and loud noise, and the similarities between the early side effects of these two agents, to our knowledge no study has investigated the role of loud noise in modulating MDMA toxicity. Therefore, in the present study, we evaluated whether cardiac effects of MDMA administration following a typical "binging" pattern are enhanced by concomitant exposure to loud noise. We selected low doses of MDMA in order to avoid gross morphological alterations, or lesions detectable under light microscopy. The myocardial alterations observed were visible only at the ultrastructural level. We found a dramatic enhancement of alterations in the mouse heart upon MDMA administration during loud noise exposure. Remarkably, this enhancement was evident both as a decrease in the threshold dose of MDMA necessary to alter the myocardial ultrastructure, and as an increase in myocardial alterations produced by a higher dose of MDMA.
Gesi
Marco
M
Department of Human Morphology and Applied Biology, University of Pisa, Pisa, Italy. m.gesi@anist.med.unipi.it
Lenzi
Paola
P
Soldani
Paola
P
Ferrucci
Michela
M
Giusiani
Alberto
A
Fornai
Francesco
F
Paparelli
Antonio
A
D000818:Animals; D004334:Drug Administration Schedule; D008401:Gas Chromatography-Mass Spectrometry; D006213:Hallucinogens / Q000008:administration & dosage / Q000633:toxicity*; D006321:Heart / Q000187:drug effects*; D006325:Heart Atria / Q000187:drug effects / Q000648:ultrastructure; D006352:Heart Ventricles / Q000187:drug effects / Q000648:ultrastructure; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009206:Myocardium / Q000473:pathology*; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage / Q000633:toxicity*; D009622:Noise / Q000009:adverse effects*; D019966:Substance-Related Disorders / Q000209:etiology / Q000473:pathology
D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine